Adicet Bio (STU:1IJA) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Adicet Bio's annualized Gross Profit for the quarter that ended in Mar. 2024 was €0.00 Mil. Adicet Bio's average Total Assets over the quarter that ended in Mar. 2024 was €229.87 Mil. Therefore, Adicet Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.

Adicet Bio Gross-Profit-to-Asset % Historical Data

The historical data trend for Adicet Bio's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio Gross-Profit-to-Asset % Chart

Adicet Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

1.22

14.72

4.04

7.71

Adicet Bio Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Adicet Bio's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Adicet Bio's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adicet Bio's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adicet Bio's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Adicet Bio's Gross-Profit-to-Asset % falls into.

Adicet Bio Gross-Profit-to-Asset % Calculation

Adicet Bio's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0	/	( (312.171	+	190.09)	/ 2 )
	=	0	/	251.1305
	=	0.00 %

Adicet Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	0	/	( (190.09	+	269.647)	/ 2 )
	=	0	/	229.8685
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Adicet Bio Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adicet Bio (STU:1IJA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (STU:1IJA) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

ACET:USA 1IJA:Germany

Address

200 Clarendon Street, Floor 6, Boston, MA, USA, 02116

Website

https://www.adicetbio.com

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.

Adicet Bio (STU:1IJA) Headlines

No Headlines